LIF R

LIF R Molekülinformation

Englischer Name	Leukemia inhibitory factor receptor	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	2	Target-Alias	LIF receptor，LIF-R，CD118
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

Englischer Name	Leukemia inhibitory factor receptor
Target-Alias	LIF receptor，LIF-R，CD118
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	2
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

LIF R Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
Fc Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
LIR-H4252	Human	HEK293	Human LIF R / CD118 Protein, Fc Tag				In den Warenkorb legen

Gesamtmenge1

Produktanfrage

LIF R Molekülhintergrund

Leukemia inhibitory factor receptor is also known as LIFR; CD118; FLJ98106; FLJ99923; LIF-R; SJS2; STWS; SWS, is the receptor for leukemia inhibitory factor (LIF). The leukemia inhibitory factor is a polyfunctional cytokine that affects the differentiation, survival, and proliferation of a wide variety of cells in the adult and the embryo. LIF action appears to be mediated through a high-affinity receptor complex composed of a low-affinity LIF binding chain (LIF receptor) and a high-affinity converter subunit, gp130. Both LIFR and gp130 are members of a family of cytokine receptors that includes components of the receptors for the majority of hematopoietic cytokines and for cytokines that affect other systems, including the ciliary neurotrophic factor, growth hormone and prolactin Defects in LIFR are the cause of Stueve-Wiedemann syndrome (SWS), a severe autosomal recessive condition and belongs to the group of the bent-bone dysplasias.

LIF R Molekülalias

LIFR,CD118,FLJ98106,FLJ99923,SJS2,STWS,SWS

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Cardiotrophin-1 (Digna Biotech/Biotecnol)	CT-1	Phase 2 Clinical	Biotecnol Sa, Digna Biotech Sl, Genentech Inc	Acute Kidney Injury; Ischemia; Liver Failure; Myocardial Reperfusion Injury	Details
MSC-1 (Northern Biologics)		Phase 1 Clinical	Mosaic Biosciences	Carcinoma, Non-Small-Cell Lung; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours	Details